Page 6 - After Pfizer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

India may approve Serum Institute's Covishield by next week even as UK examines data DCGI gives a green signal to SII, India will be the first nation to approve the Oxford vaccine under emergency use authorisation; British health regulator is still evaluating Oxford-AstraZeneca data BusinessToday.In | December 23, 2020 | Updated 13:44 IST After approval, SII may sign a supply contract with govt under the mass inoculation drive The Indian drug regulator will most likely approve Oxford/AstraZeneca's coronavirus vaccine as soon as next week. This is contrary to earlier speculations that India ...

India may approve Serum Institute's Covishield by next week even as UK examines data DCGI gives a green signal to SII, India will be the first nation to approve the Oxford vaccine under emergency use authorisation; British health regulator is still evaluating Oxford-AstraZeneca data BusinessToday.In | December 23, 2020 | Updated 13:44 IST After approval, SII may sign a supply contract with govt under the mass inoculation drive The Indian drug regulator will most likely approve Oxford/AstraZeneca's coronavirus vaccine as soon as next week. This is contrary to earlier speculations that India ...

Moderna has already moved vaccine supplies from its manufacturing plants to warehouses. Detroit/Los Angeles/New York: US distribution of Moderna Inc's COVID-19 vaccine began on Saturday, with more than 3,700 sites due to start receiving and administering shots as soon as Monday, vastly widening the rollout started last week by Pfizer Inc. Amid record coronavirus infections and deaths, Moderna has already moved vaccine supplies from its manufacturing plants to warehouses operated by distributor McKesson Corp. Workers on Saturday were packing vaccines into containers and loading them on trucks...

Day after FDA nod, US advisory panel recommends Moderna COVID-19 vaccine for adults Moderna COVID-19 Vaccine was authorised for distribution and use under emergency use on December 18; eleven members of the committee, which comprises independent health experts, voted in favour of the vaccine and 0 members voted against BusinessToday.In | December 20, 2020 | Updated 11:41 IST The ACIP advises the CDC on the populations and circumstances for which vaccines should be used US biotech firm Moderna said the US Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunisation Pr...

Serum Institute to seek DCGI approval for two full-dose regimen of Covishield SII had earlier said its vaccine candidate showed 90 per cent efficacy rate at a full dose plus a half dose regimen, while a 62 per cent efficacy rate at full two-dose regimen BusinessToday.In | December 19, 2020 | Updated 16:09 IST Serum Institute also conducted clinical trials on two full doses Pune-based vaccine giant Serum Institute of India (SII) will apply for two-dose regimen authorisation from the Drug Controller General of India (DCGI) after its partner, Oxford University, said early trial data analysis su...